{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:05:41Z","timestamp":1791295541039,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,8,6]],"date-time":"2016-08-06T00:00:00Z","timestamp":1470441600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s11899-016-0335-0","type":"journal-article","created":{"date-parts":[[2016,8,6]],"date-time":"2016-08-06T03:28:21Z","timestamp":1470454101000},"page":"348-355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia"],"prefix":"10.1007","volume":"11","author":[{"given":"Gunnar","family":"Birgeg\u00e5rd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,6]]},"reference":[{"key":"335_CR1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761\u201370.","journal-title":"J Clin Oncol"},{"key":"335_CR2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","volume":"118","author":"R Scherber","year":"2011","unstructured":"Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118:401\u20138.","journal-title":"Blood"},{"key":"335_CR3","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","volume":"123","author":"HL Geyer","year":"2014","unstructured":"Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014;123:3803\u201310.","journal-title":"Blood"},{"key":"335_CR4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1055\/s-2007-996119","volume":"23","author":"U Budde","year":"1997","unstructured":"Budde U, VAN Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost. 1997;23:425\u201331.","journal-title":"Semin Thromb Hemost"},{"key":"335_CR5","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","volume":"26","author":"G Finazzi","year":"2012","unstructured":"Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26:716\u20139.","journal-title":"Leukemia"},{"key":"335_CR6","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","volume":"120","author":"PJ Campbell","year":"2012","unstructured":"Campbell PJ, Maclean C, Beer PA, Buck G, Wheatley K, Kiladjian JJ, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012;120:1409\u201311.","journal-title":"Blood"},{"key":"335_CR7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s002770050345","volume":"75","author":"PJ Genderen VAN","year":"1997","unstructured":"VAN Genderen PJ, VAN Vliet HH, Prins FJ, VAN DE Moesdijk D, VAN Strik R, Zijlstra FJ, et al. Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma. Ann Hematol. 1997;75:215\u201320.","journal-title":"Ann Hematol"},{"key":"335_CR8","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1517\/14656566.2013.797408","volume":"14","author":"G Birgegard","year":"2013","unstructured":"Birgegard G. Pharmacological management of essential thrombocythemia. Expert Opin Pharmacother. 2013;14:1295\u2013306.","journal-title":"Expert Opin Pharmacother"},{"key":"335_CR9","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","volume":"332","author":"S Cortelazzo","year":"1995","unstructured":"Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132\u20136.","journal-title":"N Engl J Med"},{"key":"335_CR10","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128\u201333. quiz 5252.","journal-title":"Blood"},{"key":"335_CR11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12032-014-0231-1","volume":"31","author":"D Lekovic","year":"2014","unstructured":"Lekovic D, Gotic M, Milic N, Miljic P, Mitrovic M, Cokic V, et al. The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia. Med Oncol. 2014;31:231.","journal-title":"Med Oncol"},{"key":"335_CR12","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V, DE Stefano V, Betti S, Rambaldi A, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5, e369.","journal-title":"Blood Cancer J"},{"key":"335_CR13","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","volume":"124","author":"G Finazzi","year":"2014","unstructured":"Finazzi G, Carobbio A, Guglielmelli P, Cavalloni C, Salmoiraghi S, Vannucchi AM, et al. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood. 2014;124:2611\u20132.","journal-title":"Blood"},{"key":"335_CR14","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood-2008-04-153783","volume":"112","author":"A Carobbio","year":"2008","unstructured":"Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 2008;112:3135\u20137.","journal-title":"Blood"},{"key":"335_CR15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.leukres.2016.04.004","volume":"46","author":"L Gugliotta","year":"2016","unstructured":"Gugliotta L, Iurlo A, Gugliotta G, Tieghi A, Specchia G, Gaidano G, et al. Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2016;46:18\u201325.","journal-title":"Leuk Res"},{"key":"335_CR16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/ejh.12554","volume":"96","author":"J Schwarz","year":"2016","unstructured":"Schwarz J, Ovesna P, Cerna O, Kissova J, Maaloufova Soukupova J, Brychtova Y, et al. Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide. Eur J Haematol. 2016;96:98\u2013106.","journal-title":"Eur J Haematol"},{"key":"335_CR17","doi-asserted-by":"crossref","unstructured":"BUXHOFER-AUSCH, V., STEURER, M., SORMANN, S., SCHLOEGL, E., SCHIMETTA, W., GISSLINGER, B., RUCKSER, R., GASTL, G. & GISSLINGER, H. 2016. Influence of platelet and white blood cell counts on major thrombosis - Analysis from a patient registry in Essential Thrombocythemia. Eur J Haematol. * Shows that both increased WBC and platelet counts increase risk for thrombosis","DOI":"10.1111\/ejh.12759"},{"key":"335_CR18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-0038-1661206","volume":"52","author":"W Abe Andes","year":"1984","unstructured":"Abe Andes W, Noveck RJ, Fleming JS. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb Haemost. 1984;52:325\u20138.","journal-title":"Thromb Haemost"},{"key":"335_CR19","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/sj.leu.2404180","volume":"20","author":"Y Hong","year":"2006","unstructured":"Hong Y, Wang G, DEL Arroyo AG, Hernandez J, Skene C, Erusalimsky JD. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Leukemia. 2006;20:1117\u201322.","journal-title":"Leukemia"},{"key":"335_CR20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/0953710021000016339","volume":"13","author":"Y Hong","year":"2002","unstructured":"Hong Y, Erusalimsky JD. Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review. Platelets. 2002;13:381\u20136.","journal-title":"Platelets"},{"key":"335_CR21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1055\/s-2006-942756","volume":"32","author":"J Thiele","year":"2006","unstructured":"Thiele J, Kvasnicka HM, Schmitt-Graeff A. Effects of anagrelide on megakaryopoiesis and platelet production. Semin Thromb Hemost. 2006;32:352\u201361.","journal-title":"Semin Thromb Hemost"},{"key":"335_CR22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.7150\/ijms.5.87","volume":"5","author":"J Palmblad","year":"2008","unstructured":"Palmblad J, Bjorkholm M, Kutti J, Larfars G, Lofvenberg E, Markevarn B, et al. TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders. Int J Med Sci. 2008;5:87\u201391.","journal-title":"Int J Med Sci"},{"key":"335_CR23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/jth.12850","volume":"13","author":"YR Espasandin","year":"2015","unstructured":"Espasandin YR, Glembotsky AC, Grodzielski M, Lev PR, Goette NP, Molinas FC, et al. Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms. J Thromb Haemost. 2015;13:631\u201342.","journal-title":"J Thromb Haemost"},{"key":"335_CR24","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1080\/10428190802087462","volume":"49","author":"CR Rinaldi","year":"2008","unstructured":"Rinaldi CR, Martinelli V, Rinaldi P, Ciancia R, DEL Vecchio L. GATA1 is overexpressed in patients with essential thrombocythemia and polycythemia vera but not in patients with primary myelofibrosis or chronic myelogenous leukemia. Leuk Lymphoma. 2008;49:1416\u20139.","journal-title":"Leuk Lymphoma"},{"key":"335_CR25","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1111\/j.1538-7836.2010.03970.x","volume":"8","author":"M Ahluwalia","year":"2010","unstructured":"Ahluwalia M, Donovan H, Singh N, Butcher L, Erusalimsky JD. Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction. J Thromb Haemost. 2010;8:2252\u201361.","journal-title":"J Thromb Haemost"},{"key":"335_CR26","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/jth.12959","volume":"13","author":"M Ahluwalia","year":"2015","unstructured":"Ahluwalia M, Butcher L, Donovan H, Killick-Cole C, Jones PM, Erusalimsky JD. The gene expression signature of anagrelide provides an insight into its mechanism of action and uncovers new regulators of megakaryopoiesis. J Thromb Haemost. 2015;13:1103\u201312. Opens a new frontier for the understanding of anagrelide action through the gene expression profile.","journal-title":"J Thromb Haemost"},{"key":"335_CR27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0301-472X(02)00870-6","volume":"30","author":"JD Erusalimsky","year":"2002","unstructured":"Erusalimsky JD, Hong Y, Franklin R. Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)? Exp Hematol. 2002;30:625\u20136. author reply 626-7.","journal-title":"Exp Hematol"},{"key":"335_CR28","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.clinthera.2009.02.008","volume":"31","author":"PE Petrides","year":"2009","unstructured":"Petrides PE, Gisslinger H, Steurer M, Linkesch W, Krumpl G, Schuller A, et al. Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation. Clin Ther. 2009;31:386\u201398.","journal-title":"Clin Ther"},{"key":"335_CR29","doi-asserted-by":"crossref","first-page":"787","DOI":"10.5414\/CP201711","volume":"50","author":"C Besses","year":"2012","unstructured":"Besses C, Zeller W, Alvarez-Larran A, Coll R, Troy S, Purkayastha J, et al. Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 - 50 years) and elderly (>\/= 65 years) patients with essential thrombocythemia. Int J Clin Pharmacol Ther. 2012;50:787\u201396.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"335_CR30","doi-asserted-by":"crossref","unstructured":"1992. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group. Am J Med. 92, 69-76.","DOI":"10.1016\/0002-9343(92)90017-6"},{"key":"335_CR31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1055\/s-2006-939437","volume":"32","author":"G Birgegard","year":"2006","unstructured":"Birgegard G. Anagrelide treatment in myeloproliferative disorders. Semin Thromb Hemost. 2006;32:260\u20136.","journal-title":"Semin Thromb Hemost"},{"key":"335_CR32","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJM198805193182002","volume":"318","author":"MN Silverstein","year":"1988","unstructured":"Silverstein MN, Petitt RM, Solberg LA, Fleming Jr JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med. 1988;318:1292\u20134.","journal-title":"N Engl J Med"},{"key":"335_CR33","first-page":"40","volume":"77","author":"CL Balduini","year":"1992","unstructured":"Balduini CL, Bertolino G, Noris P, Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica. 1992;77:40\u20133.","journal-title":"Haematologica"},{"key":"335_CR34","first-page":"315","volume":"77","author":"MG Mazzucconi","year":"1992","unstructured":"Mazzucconi MG, DE Sanctis V, Chistolini A, Dragoni F, Mandelli F. Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica. 1992;77:315\u20137.","journal-title":"Haematologica"},{"key":"335_CR35","first-page":"51","volume":"34","author":"RM Petitt","year":"1997","unstructured":"Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol. 1997;34:51\u20134.","journal-title":"Semin Hematol"},{"key":"335_CR36","first-page":"520","volume":"89","author":"G Birgegard","year":"2004","unstructured":"Birgegard G, Bjorkholm M, Kutti J, Larfars G, Lofvenberg E, Markevarn B, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica. 2004;89:520\u20137.","journal-title":"Haematologica"},{"key":"335_CR37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33\u201345.","journal-title":"N Engl J Med"},{"key":"335_CR38","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"121","author":"H Gisslinger","year":"2013","unstructured":"Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013;121:1720\u20138. The ANAHYDRET study: one of two prospective randomized trials of ANA vs HC showing non-inferiority of ANA.","journal-title":"Blood"},{"key":"335_CR39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.leukres.2004.10.002","volume":"29","author":"SM Fruchtman","year":"2005","unstructured":"Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res. 2005;29:481\u201391.","journal-title":"Leuk Res"},{"key":"335_CR40","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","volume":"97","author":"EC Storen","year":"2001","unstructured":"Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001;97:863\u20136.","journal-title":"Blood"},{"key":"335_CR41","first-page":"231","volume":"62","author":"LI Kornblihtt","year":"2002","unstructured":"Kornblihtt LI, Vassallu PS, Heller P, Molinas FC. Treatment of essential thrombocythemia with anagrelide: a ten-year experience. Medicina (B Aires). 2002;62:231\u20136.","journal-title":"Medicina (B Aires)"},{"key":"335_CR42","doi-asserted-by":"crossref","unstructured":"IURLO, A., CATTANEO, D., OROFINO, N., BUCELLI, C., FABRIS, S. & CORTELEZZI, A. 2016. Anagrelide and Mutational Status in Essential Thrombocythemia. BioDrugs.","DOI":"10.1007\/s40259-016-0170-9"},{"key":"335_CR43","first-page":"2687","volume":"9","author":"N Cascavilla","year":"2015","unstructured":"Cascavilla N, DE Stefano V, Pane F, Pancrazzi A, Iurlo A, Gobbi M, et al. Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. Drug Des Devel Ther. 2015;9:2687\u201394.","journal-title":"Drug Des Devel Ther"},{"key":"335_CR44","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/cncr.20646","volume":"101","author":"M Steurer","year":"2004","unstructured":"Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlogl E, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer. 2004;101:2239\u201346.","journal-title":"Cancer"},{"key":"335_CR45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF02685904","volume":"24","author":"M Hultdin","year":"2007","unstructured":"Hultdin M, Sundstrom G, Wahlin A, Lundstrom B, Samuelsson J, Birgegard G, et al. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Med Oncol. 2007;24:63\u201370.","journal-title":"Med Oncol"},{"key":"335_CR46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1179\/1607845412Y.0000000023","volume":"18","author":"E Ejerblad","year":"2013","unstructured":"Ejerblad E, Kvasnicka HM, Thiele J, Andreasson B, Bjorkholm M, Lofvenberg E, et al. Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up. Hematology. 2013;18:8\u201313. Long term prospective follow-up study showing the difference in prognosis between true ET and early PMF.","journal-title":"Hematology"},{"key":"335_CR47","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179\u201384.","journal-title":"J Clin Oncol"},{"key":"335_CR48","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1016\/0006-2952(88)90054-8","volume":"37","author":"E Gillespie","year":"1988","unstructured":"Gillespie E. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. Biochem Pharmacol. 1988;37:2866\u20138.","journal-title":"Biochem Pharmacol"},{"key":"335_CR49","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijcard.2015.10.043","volume":"203","author":"G Tortorella","year":"2016","unstructured":"Tortorella G, Calzolari M, Tieghi A, Muia N, Piccin A, Gugliotta L. Acute coronary syndrome (ACS) in patients with essential thrombocytemia (ET). What is the best treatment? Int J Cardiol. 2016;203:225\u20137.","journal-title":"Int J Cardiol"},{"key":"335_CR50","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.leukres.2011.06.030","volume":"35","author":"L Gugliotta","year":"2011","unstructured":"Gugliotta L, Tieghi A, Tortorella G, Scalzulli PR, Ciancia R, Lunghi M, et al. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leuk Res. 2011;35:1557\u201363.","journal-title":"Leuk Res"},{"key":"335_CR51","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.leukres.2015.03.014","volume":"39","author":"G Tortorella","year":"2015","unstructured":"Tortorella G, Piccin A, Tieghi A, Marcheselli L, Steurer M, Gastl G, et al. Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study. Leuk Res. 2015;39:592\u20138. Study of the relative lack of importance of cardiovascular monitoring in ANA-treated patients.","journal-title":"Leuk Res"},{"key":"335_CR52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/ejh.12210","volume":"92","author":"J Rey","year":"2014","unstructured":"Rey J, Viallard JF, Keddad K, Smith J, Wilde P, Kiladjian JJ. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France. Eur J Haematol. 2014;92:127\u201336. Investigates efficacy and toxicity of different ANA regimes for switching from other CRT to ANA, showing the importance of using label recommendations.","journal-title":"Eur J Haematol"},{"key":"335_CR53","first-page":"1306","volume":"89","author":"MG Mazzucconi","year":"2004","unstructured":"Mazzucconi MG, Redi R, Bernasconi S, Bizzoni L, Dragoni F, Latagliata R, et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica. 2004;89:1306\u201313.","journal-title":"Haematologica"},{"key":"335_CR54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000264611","volume":"33","author":"S Schmitz","year":"2010","unstructured":"Schmitz S, Stauch M, Schlag R. Anagrelide for the treatment of thrombocythaemia in daily clinical practice: a post-marketing observational survey on efficacy and safety performed in Germany. Onkologie. 2010;33:39\u201344.","journal-title":"Onkologie"},{"key":"335_CR55","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2012.083097","volume":"99","author":"L Gugliotta","year":"2014","unstructured":"Gugliotta L, Besses C, Griesshammer M, Harrison C, Kiladjian JJ, Coll R, et al. Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study. Haematologica. 2014;99:679\u201387.","journal-title":"Haematologica"},{"key":"335_CR56","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.leukres.2012.11.004","volume":"37","author":"C Besses","year":"2013","unstructured":"Besses C, Kiladjian JJ, Griesshammer M, Gugliotta L, Harrison C, Coll R, et al. Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. Leuk Res. 2013;37:162\u20138. Large European study of treatment patterns in ET, showing that ANA is preferentially used in younger ET patients.","journal-title":"Leuk Res"},{"key":"335_CR57","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/cncr.21900","volume":"106","author":"J Samuelsson","year":"2006","unstructured":"Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006;106:2397\u2013405.","journal-title":"Cancer"},{"key":"335_CR58","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/028418602317314064","volume":"41","author":"M Merup","year":"2002","unstructured":"Merup M, Aberg W, Lofvenberg E, Svensson E, Engman K, Paul C, et al. Symptoms, symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferon-alpha. Acta Oncol. 2002;41:50\u20135.","journal-title":"Acta Oncol"},{"key":"335_CR59","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.leu.2400931","volume":"12","author":"S Sacchi","year":"1998","unstructured":"Sacchi S, Gugliotta L, Papineschi F, Liberati AM, Rupoli S, Delfini C, et al. Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET. Leukemia. 1998;12:289\u201394.","journal-title":"Leukemia"},{"key":"335_CR60","first-page":"1333","volume":"90","author":"C Langer","year":"2005","unstructured":"Langer C, Lengfelder E, Thiele J, Kvasnicka HM, Pahl HL, Beneke H, et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica. 2005;90:1333\u20138.","journal-title":"Haematologica"},{"issue":"Suppl 2","key":"335_CR61","doi-asserted-by":"crossref","first-page":"S300","DOI":"10.1016\/j.clml.2013.05.015","volume":"13","author":"IE Ahn","year":"2013","unstructured":"Ahn IE, Natelson E, Rice L. Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide. Clin Lymphoma Myeloma Leuk. 2013;13 Suppl 2:S300\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-016-0335-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-016-0335-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-016-0335-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T21:50:12Z","timestamp":1600984212000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-016-0335-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,6]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["335"],"URL":"https:\/\/doi.org\/10.1007\/s11899-016-0335-0","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,6]]}}}